Latest Breaking News On - Yves sabbagh - Page 1 : vimarsana.com

Inozyme Pharma To Present Recently Announced Data From Phase 1/2 Trials Of INZ-701 In Adults With ENPP1 Deficiency And ABCC6 Deficiency (PXE) At Upcom...

BOSTON, May 23, 2024 (GLOBE NEWSWIRE)

Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate to.

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

Inozyme Pharma Inc. (INZY) to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial

Inozyme Pharma Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

- Rapid and significant increase in plasma pyrophosphate (PPi) levels observed in all three subjects in lowest dose coh.

Inozyme Pharma Inc. (INZY) Reports Positive Prelim Data from Phase 1/2 Clinical Trial of INZ-701

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

Message : Required fields BOSTON, May 07, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today presented preclinical data suggesting the utility of its lead clinical development candidate, INZ-701, as a potential treatment for ABCC6 Deficiency. The data, presented at the virtual European Calcified Tissue Society Annual Congress (ECTS, May 6-8), are the first to show that an enzyme replacement therapy (ERT) increased plasma pyrophosphate (PPi) levels and reduced calcification in an animal model of ABCC6 Deficiency. ABCC6 Deficiency is a rare, inherited disorder that can present as generalized arterial calcification of infancy (GACI) type 2 in infants and as pseudoxanthoma elasticum (PXE) in children and adults. This is one of several disorders with significant decrease in plasma PPi levels, a potent regulator of mineralization. In patients with ABCC6

Inozyme Pharma Expands its Scientific Advisory Board

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Inozyme Pharma Expands its Scientific Advisory Board Inozyme Pharma Inc.April 1, 2021 GMT BOSTON, April 01, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today changes to its scientific advisory board (SAB), including the addition of three leading key opinion leaders with specific expertise in the company’s lead indications: W Charles O’Neill IV, M.D., Director of the Ultrasonography Program in the Renal Division at Emory University School of Medicine